Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688906 · ClinicalTrials.gov registry record
AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test
A clinical trial, sponsored by Freenome Holdings.
- Completed
- Registry status
- 3,275
- Enrollment target
NCT03688906: Completed study, sponsored by Freenome Holdings.
NCT03688906 is a clinical trial that has completed, run by Freenome Holdings. The registered enrollment target is 3,275 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03688906 has completed, sponsored by Freenome Holdings.
- COMPLETED
- Registry status
- 3,275 participants
- Enrollment target
Study Summary
Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas.
Primary Outcome
Clinically annotated plasma samples from participants will undergo multi-omic analyses to characterize cell-free biomarkers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,275 participants |
| Start Date | 2018-01-12 |
| Est. Completion | 2019-11-25 |
What the finished NCT03688906 record still lists
NCT03688906 is an observational study that tracks outcomes without assigning an intervention. Its 3,275 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03688906 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03688906 about?
NCT03688906 is a clinical study titled "AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test". Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from ...
What is the current status of trial NCT03688906?
This trial is currently completed. The enrollment target is 3,275 participants. The study started on 2018-01-12. Estimated completion is 2019-11-25.
Who is sponsoring clinical trial NCT03688906?
This trial is sponsored by Freenome Holdings, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04077762 · 3,266 participants · NA
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
- NCT06543446 · 3,290 participants · NA
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI